BACKGROUND: The three Food and Drug Administration (FDA)-approved anti-tumor necrosis factor drugs (anti-TNFs) for Crohn's disease (CD) have not been directly compared. AIM: To compare the efficacy of the three anti-TNFs for CD in clinical practice. METHODS: Retrospective review of patients initiated on anti-TNF between 2004 and 2008. Disease activity, quality of life, and remission rates were compared between groups over 1 year. RESULTS: Sixty patients with CD were initiated on anti-TNF from 2004 to 2008: 31 on infliximab (IFX) and 29 on adalimumab (ADA) or certolizumab pegol (CTZ). More patients in the ADA/CTZ scores group had prior exposure to anti-TNF (76 versus 10%, p < 0.01). Mean Harvey-Bradshaw Index (HBI) scores in the IFX group were lower than in the ADA/CTZ group at 12 months (2.72 ± 3.34 versus 5.63 ± 5.33, p = 0.03). At 12 months, more IFX patients were in remission compared with those on ADA/CTZ (88 versus 53%, p ≤ 0.01). Mean short inflammatory bowel disease questionnaire (SIBDQ) scores were not different between the IFX and ADA/CTZ groups at 12 months. Stratified analyses and logistic regression based on prior anti-TNF use did not show differences in remission rates at any time point post-baseline between groups. CONCLUSIONS: After adjustment for prior anti-TNF there was no difference in remission rates between the IFX and ADA/CTZ groups at any time point post-baseline. This suggests that differences between groups were accounted for by a higher rate of prior anti-TNF in the ADA/CTZ group. Our results should be reviewed with caution given the small sample size.
BACKGROUND: The three Food and Drug Administration (FDA)-approved anti-tumornecrosis factor drugs (anti-TNFs) for Crohn's disease (CD) have not been directly compared. AIM: To compare the efficacy of the three anti-TNFs for CD in clinical practice. METHODS: Retrospective review of patients initiated on anti-TNF between 2004 and 2008. Disease activity, quality of life, and remission rates were compared between groups over 1 year. RESULTS: Sixty patients with CD were initiated on anti-TNF from 2004 to 2008: 31 on infliximab (IFX) and 29 on adalimumab (ADA) or certolizumab pegol (CTZ). More patients in the ADA/CTZ scores group had prior exposure to anti-TNF (76 versus 10%, p < 0.01). Mean Harvey-Bradshaw Index (HBI) scores in the IFX group were lower than in the ADA/CTZ group at 12 months (2.72 ± 3.34 versus 5.63 ± 5.33, p = 0.03). At 12 months, more IFXpatients were in remission compared with those on ADA/CTZ (88 versus 53%, p ≤ 0.01). Mean short inflammatory bowel disease questionnaire (SIBDQ) scores were not different between the IFX and ADA/CTZ groups at 12 months. Stratified analyses and logistic regression based on prior anti-TNF use did not show differences in remission rates at any time point post-baseline between groups. CONCLUSIONS: After adjustment for prior anti-TNF there was no difference in remission rates between the IFX and ADA/CTZ groups at any time point post-baseline. This suggests that differences between groups were accounted for by a higher rate of prior anti-TNF in the ADA/CTZ group. Our results should be reviewed with caution given the small sample size.
Authors: D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer Journal: N Engl J Med Date: 1999-05-06 Impact factor: 91.245
Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245
Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Jean-Frédéric Colombel; Remo Panaccione; Geert D'Haens; Ju Li; Marie R Rosenfeld; Jeffrey D Kent; Paul F Pollack Journal: Ann Intern Med Date: 2007-04-30 Impact factor: 25.391
Authors: Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682
Authors: William J Sandborn; Brian G Feagan; Simeon Stoinov; Pieter J Honiball; Paul Rutgeerts; David Mason; Ralph Bloomfield; Stefan Schreiber Journal: N Engl J Med Date: 2007-07-19 Impact factor: 91.245
Authors: Stefan Schreiber; Mani Khaliq-Kareemi; Ian C Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn Journal: N Engl J Med Date: 2007-07-19 Impact factor: 91.245
Authors: R W Stidham; T C H Lee; P D R Higgins; A R Deshpande; D A Sussman; A G Singal; B J Elmunzer; S D Saini; S Vijan; A K Waljee Journal: Aliment Pharmacol Ther Date: 2014-04-20 Impact factor: 8.171
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Guergana Savova; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Katherine P Liao; Shawn N Murphy Journal: Inflamm Bowel Dis Date: 2016-04 Impact factor: 5.325
Authors: Jason P Gordon; Phil C McEwan; Andy Maguire; Daniel M Sugrue; Jorge Puelles Journal: Eur J Gastroenterol Hepatol Date: 2015-07 Impact factor: 2.566
Authors: Evelyn Sayuri S Chinem; Barbara C Esberard; Andre da L Moreira; Tatiana G Barbassa; Guilherme M da Cunha; Antonio Jose de V Carneiro; Heitor S de Souza; Ana Teresa P Carvalho Journal: Gastroenterol Res Pract Date: 2019-12-17 Impact factor: 2.260